Brief: Freeline Announces First Patient Dosed In The Phase 1/2 B-Lieve Dose-Confirmation Trial In Hemophilia B

Freeline Therapeutics Holdings

09/03/2022 15:12

March 9 (Reuters) - Freeline Therapeutics Holdings PLC  FRLN.O :
    * FREELINE ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1/2 B-LIEVE DOSE-CONFIRMATION TRIAL IN
HEMOPHILIA B
    * FREELINE THERAPEUTICS - ON TRACK TO COMPLETE DOSING OF THE FIRST COHORT AND SHARE INITIAL
DATA
BY THE END OF THE FIRST HALF OF 2022
    * FREELINE THERAPEUTICS - ON TRACK TO START PIVOTAL PHASE 3 TRIAL IN 2023

Source text - https://bit.ly/3sVukAA
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))